Clinical Trial Update: Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating tadalafil and lenalidomide maintenance with or without MILs in high-risk multiple myeloma; trial completed with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Lenalidomide (lenalidomide)
• TADALAFIL (TADALAFIL)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Multiple Myeloma | Phase 2 | Status: COMPLETED | Results posted: 2020-06-29